U.K. MHRA Awards Tern Therapeutics Innovation Passport for TTX-381 to Accelerate Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease
U.K. MHRA awards Tern Therapeutics Innovation Passport for TTX-381
Tern Therapeutics is a biotechnology company developing gene therapies for rare diseases. TTX-381 is a novel one-time investigational gene therapy product being developed for the treatment of vision loss in CLN2 disease and clinical trials have been ongoing at Great Ormond Street Hospital.
Tern have now been granted the Innovation Passport under the accelerated Innovative Licensing and Access Pathway (ILAP) by the UK Medicines and Healthcare products Regulatory Agency (MHRA) (7cb293_5aa3544682ac44f3885dabaf8cb9e9fc.pdf).
This is the entry point to the ILAP which aims to accelerate the process of getting transformative new medicines to market and facilitate patient access. The award was given as TTX-381 is innovative, it has the potential to substantially improve patient health outcomes and CLN2 vision loss is seriously debilitating with a significant unmet clinical need.
TTX-381 has also been granted Regenerative Medicine Advance Therapy (RMAT) and Fast Track Designations by the U.S. Food and Drug Administration (FDA). You can read the full press release from Tern here (News & Publications | Tern Therapeutics).
This does not mean the treatment is approved; however, this is an important early step that shows potential and supports a more patient-focused path forward. We hope it will encourage other companies to develop therapies for other forms of Batten disease. BDFA are working closely with Tern Therapeutics, and we will continue to share updates as we have them.
Please do get in touch if you have any questions.